Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Binnopharm
Group enters into agreement to acquire two anti-bacterial brands from Dr. Reddy's in the Russia & CIS region"
This is for your information.
| /s/ Vivek Mittal | |
| Vivek Mittal | |
| Global General Counsel and Compliance Officer |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
Binnopharm Group enters into agreement to acquire
brands from Dr. Reddy's in the Russia & CIS region
Moscow, Russia and Hyderabad India; February
21, 2022: The Sistema Group company (LSE: SSA, MOEX: AFKS), Binnopharm Group, one of the leading pharmaceutical production
companies in Russia via its affiliate Joint Stock Company Alium', and Dr. Reddy's Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), an integrated
global pharmaceutical company, today announced the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial
medicines under the Ciprolet and Levolet brands from Dr. Reddy's in Russia, Uzbekistan and Belarus. The portfolio
includes various dosage forms such as tablets, solution for infusions and eye drops.
Rustem Muratov, CEO of the Binnopharm Group
said: "The acquisition of Ciprolet and Levolet is an important step to enhance our position in the antibiotics
market, one of the key market segments for Binnopharm Group. These strong brands have already had the trust of millions of consumers
- according to independent analyst estimation they are leaders in their market segments. They will be a valuable complement
to our portfolio of antibacterial products. We are also acquiring rights to these products in Belarus and Uzbekistan in line with
our strategic goal to strengthen presence in the international markets."
M.V. Ramana, CEO - Branded Markets
(India & Emerging Markets), said: "Our Russia and CIS markets continue to be strong performers for the company.
This deal is a step towards divesting brands in non-core areas in order to consolidate and strengthen our play further in our key
focus therapy areas of gastro-enterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women's
health. This will help us accelerate access to affordable and innovative medicines in the region in these segments in keeping with
our purpose of Good Health Can't Wait'."
During the transition period, Dr. Reddy's will
continue to supply the product to Binnopharm Group to ensure availability in the market.
About Binnopharm Group
Binnopharm Group was founded in 2020 through
consolidation of pharmaceutical assets of Sistema PJSFC., Binnopharm Group is Russia's largest producer of antibiotics and
the No. 1 manufacturer of products intended for CIS exports, a Top 3 Russian pharmaceutical company (according to AlphaRM). The
company has 5 production assets in different Russian regions. The assets manufacture a total of 200+ pharmacological groups in
various dosage forms (from tablets and capsules to ointments, gels, suppositories, infusion solutions, etc.) and boast one of
the largest portfolios among Russian manufacturers - 450+ marketing authorisations. For more information, log on to: https://en.binnopharmgroup.ru.
Contact information for Binnopharm Group:
| Investor Relations | Media Relations |
| Nikolay Minashin | Elena Shipilova |
| nminashin@binnopharmgroup.ru | eshipilova@binnopharmgroup.ru |
About Dr. Reddy's Laboratories:
Dr. Reddy's Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services,
generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include
- USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Contact information for Dr. Reddy's:
| Investor Relations | Media Relations |
| Amit Agarwal | Usha Iyer |
| amita@drreddys.com | ushaiyer@drreddys.com |